DalCor Pharmaceuticals
PrivateLast Round
Seed Round
Jul 30, 2026
Total Funding Raised
$230M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
DalCor Pharmaceuticals is a biopharmaceutical company that develops dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that specifically targets patients with the ADCY9 AA genotype.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Precision Medicine, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
DalCor Pharmaceuticals Comparables
Compare DalCor Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cardurion Pharmaceuticals | 71% | |
| Abcentra | 68% | |
| Novo Nordisk | 67% |
DalCor Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed Round | Jul 30, 2026 | ||||
| Series D | Sep 13, 2023 | ||||
| Series B | Apr 19, 2016 | ||||
| Series A | Nov 1, 2015 |
Key People
Founding team and executive leadership
DalCor Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Series D |
| CTI Life Sciences Fund | Series D, Series B |
| Investissement Québec | Series D |
| Fonds de solidarité FTQ | Series D, Series B |
| Caisse de dépôt et placement du Québec | Series B |
| Caisse de dépôt et placement du Québec | Series B |
| Sanderling Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 30, 2026
$7M round raised
Recent news
Latest coverage and updates
- receives_financingSep 10, 2026
In Aug '26, DalCor Pharmaceuticals raises $6.96M in venture funding.
DalCor Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about DalCor Pharmaceuticals's valuation, stock price, and market status.
Is DalCor Pharmaceuticals a public or private company?
DalCor Pharmaceuticals is a private company.
What is the current stock price of DalCor Pharmaceuticals?
DalCor Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks DalCor Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is DalCor Pharmaceuticals worth (valuation)?
Valuation information for DalCor Pharmaceuticals is not publicly available.
Can I buy DalCor Pharmaceuticals stock?
DalCor Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was DalCor Pharmaceuticals's last funding round?
DalCor Pharmaceuticals's most recent funding round was Seed Round on July 30, 2026.
Who are the main investors in DalCor Pharmaceuticals?
Key investors in DalCor Pharmaceuticals include CTI Life Sciences Fund, Investissement Québec, Fonds de solidarité FTQ, Caisse de dépôt et placement du Québec, Caisse de dépôt et placement du Québec.
Will DalCor Pharmaceuticals IPO soon?
No public IPO plans have been announced for DalCor Pharmaceuticals.
How can I track DalCor Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in DalCor Pharmaceuticals's shares on secondary markets.